Clinical Trials
Eye Surgery Associates (ESA) provides services for Phase I (including first in human), II, III and IV clinical trials. We collaborate with CROs, universities, hospitals and trial sponsors, including the provision of an Australian site for global trials.
Our experienced research team includes ophthalmologists, accredited orthoptists/testers, study coordinators, administrative support, equipment management and IT support staff who provide research services across our four sites. We provide ophthalmic diagnostic testing, assessments, procedures and surgery for trials and understand the compliance and regulatory requirements involved.
We can provide masked and unmasked investigators and arrange specialist and staff back-up for continuity of service and to review complications. All members of our research team are GCP certified. Our administrative support can create source documents if required.
We welcome clinical trial organisations/sponsors to consider ESA when choosing a research partner who can provide ophthalmology services. For further information please contact Dr Nicholas Voudouris (CEO) at ESA.
Currently Recruiting Studies
Eye Surgery Associates is in the process of reviewing upcoming studies. If you would like to participate in future studies, please continue to watch this space for new updates.
Completed Studies
Development of new geographic atrophy in patients with neovascular (wet) age-related macular degeneration: a comparison of ranibizumab and aflibercept.
A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Effectiveness of the XEN45 Glaucoma Treatment System in Patients with Angle Closure Glaucoma
Capella 3D Eye model data pilot study
A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients with Open-Angle Glaucoma or Ocular Hypertension
A 3-Part, First-in-human, Double-Blind, Randomized, and Placebo-Control Study Assessing the Safety, Tolerability, and Efficacy of TO-O-1001 Ophthalmic Solution in Healthy Subjects and in Patients with Open-Angle Glaucoma or Ocular Hypertension
A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of ABX-002 in Healthy Adult Subjects
A multicenter, open-label, phase I dose escalation study to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of YH002 in combination with YH001 in subjects with advanced solid tumors
A First-in-Human (FIH), Open-Label, Phase 1/2 Dose Escalation and Expansion Study of ADG126, ADG126 in Combination with Toripalimab, and ADG126 in Combination with ADG106 in Patients with Advanced/Metastatic Solid Tumors
Open-Label, Parallel Single-Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Tinlarebant in Elderly Healthy Volunteers
A Phase 1, Open-Label, Dose Escalation Study of ADG116 in Patients with Advanced/Metastatic Solid Tumors
A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression
A Double-Blind, Phase 1, Placebo-Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of ADX-914 in Healthy Participants
A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression
Phase I, Open-Label, Multi-Centre Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of GSK2798745 after 28 Day (with an optional additional 8 Week) Repeat Oral Administration to Adults with Diabetic Macular Edema
A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination with Anti-Cancer Treatments in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) - DREAMM5.
A Phase 1 Study to Evaluate the Pharmacokinetics and Pharmacodynamics of GS-9688 upon Co-administration with a Representative Proton Pump Inhibitor or H2-Receptor Antagonist
Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumour Activity of the Anti-OX40 Agonist Monoclonal Antibody BGB-A445 in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors.
An Open-label Phase 1b Cross-over Pharmacokinetic Relative Bioavailability Study Comparing 2 Formulations of STG-001 in Healthy Subjects
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose in Healthy Volunteers and Autosomal Dominant Polycystic Kidney Disease Subjects Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Food Effect of Single Ascending Doses and Multiple Ascending Doses of EHP-101 in Healthy Subjects
A Randomized, Double-Masked (Sponsor-Open), Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Escalating Single Doses and Multiple Ascending Doses of STG-001 in Healthy Subjects